Four Key Factors to Consider when Choosing an Effective Regulatory Outsourcing Partner
A decline in revenues from approved products and rising competition in generics are adding pressure to pharmaceutical, biotechnology and medical device companies and their internal resources. Company resources continue to shrink and approval processes and postapproval requirements have become more complex. This has led companies to look for additional support and expertise for clearing regulatory hurdles to commercialisation and for keeping approved products on the market.
While it's often tempting for pharmaceutical companies to keep development and regulatory processes in-house, outsourcing provides a variety of solutions. Tapping into outside expertise uniquely positions organisations to have a competitive advantage to guide products to approval and meet postapproval requirements. Furthermore, it saves valuable time and allows internal teams to focus on other pipeline projects. When considering an outsourcing partner, companies need to make sure the partner they choose is a good fit for their business, needs and budgets.
The Cardinal Health Regulatory Sciences team recently published a white paper that explores the four key factors that help pharmaceutical and biotech companies understand the why, what and how of selecting a successful regulatory partner.
1. Knowing when to consider outsourcing regulatory services; for example, when you need to augment the expertise of your current staff; expand capacity; overcome unique regulatory challenges; or manage costs by only using outsourced regulatory expertise on an as-needed basis.
2. What functions are best outsourced — theoretically, the entire preapproval and postapproval technical writing process can be outsourced. But more practically, it makes the most sense to outsource those regulatory approval functions that require a high level of expertise or are resource intensive.
3. How pharmaceutical and biotech companies can benefit — whether it's immediate access to highly experienced consultants or additional capacity to address unforeseen challenges, outsourcing regulatory consultation services can offer a broad array of benefits.
4. How to select the right partner for your needs — it's important to start your search for an outsourcing partner early, and to make sure you're asking the right questions to get the answers you need to help you make the best choice.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance